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REVIEWS
Cardiac resynchronization therapy: 
which device to implant?
Resynchronisation cardiaque : quelle prothèse implanter ?
C. Leclercq, C. Mabo, J.C. Daubert
Département de cardiologie et maladies vasculaires, Centre cardio-pneumologique, 
CHU Rennes, France.
Summary
Cardiac resynchronization therapy is now a validated treatment for patients with moderate to
severe heart failure despite optimal drug treatment with left ventricular systolic dysfunction
and cardiac dyssynchrony defined by wide QRS greater than 120 ms. Once an indication for
cardiac resynchronization therapy has been confirmed the choice of the most appropriate
device (pacemaker or intracardiac cardioverter defibrillator (ICD)) needs to be made. In heart
failure patients the risk of sudden death, mainly but not always related to arrhythmic cause is
high. Previous studies of primary prevention of sudden cardiac death in patients with a poor left
ventricular function have shown that ICD therapy significantly reduces overall mortality and
arrhythmic mortality. However patients candidates to cardiac resynchronization therapy are
different from those included in the ICDs trials because they are older and have more
comorbidities. The choice of the devices has to consider the potential benefit of the therapy,
the comorbidities, the life expectancy but also the cost-effectiveness and the potential
complications related to the device. Now, new devices provide information about the
hemodynamic status of this heart failure population and thus provide an early detection of
heart failure decompensation. The development of home monitoring should alert very early the
physicians of the occurrence of a heart failure decompensation and thus to avoid recurrent
hospitalisations for heart failure decompensation. 
© 2008 Published by Elsevier Masson SAS.
Résumé
la resynchronisation cardiaque est une technique aujourd’hui validée chez les patients en
insuffisance cardiaque sévère malgré un traitement médical optimal avec dysfonction
ventriculaire gauche systolique et un asynchronisme cardiaque défini par une durée des QRS
supérieure à 120 ms. Une fois l’indication de resynchronisation cardiaque retenue, le choix
de la prothèse la plus approprié (stimulateur ou défibrillateur) se pose. Les données de la
littérature ont montré que ces patients sont exposés à la mort subite qui est le plus souvent,
mais pas toujours, d’origine rythmique. Les études de prévention primaire ont montré le
bénéfice significatif du défibrillateur implantable sur la mortalité globale et sur la
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mortalité rythmique. Cependant les patients candidats à la resynchronisation cardiaque
sont différents des patients inclus dans les études qui ont démontré le bénéfice du
défibrillateur automatique implantable en préventio primaire avec notamment un âge plus
élevé et de nombreuses comorbidités associées. Le choix sera donc orienté en fonction du
bénéfice attendu et des pathologies associées et à discuter au cas par cas en tenant
également compte de considérations médico-économiques et des complications
potentielles de chaque type de prothèse. Les nouvelles générations de prothèse permettent
également d’avoir des informations pertinentes sur le statut hémodynamique de ces
patients insuffisants cardiaques et donc de détecter plus tôt les décompensations
cardiaques. Le développement de  la télécardiologie  devrait permettre aux médecins en
charge des patients d’être informés très tôt de la dégradation hémodynamique des patients
et d’éviter des hospitalisations itératives. 
© 2008 Published by Elsevier Masson SAS.
Introduction
When implemented in patients with advanced, drug-
refractory congestive heart failure (CHF) due to left ven-
tricular (LV) systolic dysfunction and ventricular dyssyn-
chrony (defined by a ≥120 ms QRS duration) (1,2), car-
diac resynchronizat ion therapy (CRT) al leviates
symptoms, increases exercise capacity and improves qua-
lity of life (3-7). CRT also exerts salutary effects on LV
remodeling within 3 months, with significant decreases
in LV end-systolic and end-diastolic volumes, and a con-
siderable increase in LV ejection fraction (EF) (3-7). More
importantly, recent trials specifically designed to eva-
luate the effects of CRT on morbidity and mortality have
demonstrated a significant decrease in hospitalization
rates, particularly for decompensated CHF, and a signifi-
cant decrease in the risk of death from all-causes and
sudden cardiac death, including cases where CRT was not
associated with cardioversion and defibrillation (6-8).
Finally, various analyses have shown that CRT is cost-
effective despite the high cost of the devices (9,10).
Recently issued European and North American guidelines
for the treatment of chronic CHF recommend CRT in
patients presenting in New York Heart Association (NYHA)
CHF functional class III or IV despite optimal drug treat-
ment, with a depressed LV function and dilated LV, and
>120 ms QRS on surface electrocardiogram (ECG). The
level of recommendation is particularly high with respect
to alleviation of symptoms and lowering of hospitaliza-
tion rates, as well as reducing mortality (1,2). It is, the-
refore, predictable that CRT will markedly increase over
the next few years. 
Technological progress in the field of CRT has been
particularly prominent over the past 10 years. New, spe-
cifically designed and dedicated tools, such as guiding
sheaths to catheterize the coronary sinus or over-the-
wire LV stimulation leads, have considerably increased
the LV lead implant success rate, which, in large trials,
reaches 90% (6,7). Likewise, pulse generators have mar-
kedly evolved over the past 15 years with the develop-
ment of atrio-biventricular defibrillators (CRT-D), the
availability of completely independent LV and right ven-
tricular (RV) channels, as well as CHF diagnostic and pro-
gnostic tools. Therefore, once an indication for CRT has
been confirmed, the choice of the most appropriate
device needs to be made.




The choice of a CRT-D hinges on the prevalence of sudden
cardiac death among patients suffering from CHF, which, in
various clinical studies conducted in the past 20 years, has
ranged between 35 and 45% (10-15). It is noteworthy that
this prevalence has decreased in the last few decades, as a
result of the beneficial effects conferred by pharmacologic
intervention, including beta-adrenergic blockade, spirolo-
nactone and, more recently, eplerenone (11-15).
The MERIT-HF trial has shown that, among all fatal events,
the proportion of sudden death was inversely correlated
with severity of CHF. Thus, 64% of patients in NYHA functio-
nal class II suffered sudden death compared to 59% in class
III and 33% in class IV, in contrast to 56% of deaths due to
end stage CHF. Conversely, only 12% and 26% of deaths
were heart failure deaths among patients in functional clas-
ses II and III, respectively (12)<last two sentences do not
correlate?>. The MUSTIC trial showed that, in candidates
for CRT, sudden death accounted for 50% of fatal cardiovas-
cular events (16), while in CARE-HF, 35% of deaths were
sudden at the end of a mean follow-up of 29 months (8).
These observations raise the issue of the systematic implan-
tation of a CRT-D in all candidates for CRT. However, des-
pite the prominent representation of ventricular tachyar-
rhythmias among the various causes of sudden death,
ventricular defibrillation cannot prevent all events, since
other mechanisms, such as asystole or electro-mechanical
dissociation might be implicated.
The choice of device hinges, first of all, on whether the
implant is indicated for primary or secondary prevention.
Secondary prevention indications pertain to survivors of
out-of-hospital cardiac arrest or to patients who suffer from
hemodynamically unstable ventricular tachyarrhythmias.
The secondary prevention AVID, CASH and CIDS trials
demonstrated a 20-30% lowering of overall mortality and
33-59% decrease in arrhythmic deaths by implantable car-
dioverter defibrillators (ICD) (17-19). Therefore, CRT candi-
dates who have a secondary prevention indication for an
ICD should undergo implantation of a CRT-D. The clinical
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The issue of primary prevention in patients presenting
with CHF is more complicated. One important variable that
needs to be considered is the ischemic versus non-ischemic
etiology of the underlying cardiomyopathy. The MADIT I,
MUSTT and MADIT II trials have all confirmed the benefit
conferred by ICD in survivors of myocardial infarction (MI)
who have developed an ischemic cardiomyopathy (21-23).
MADIT I and MUSTT included patients with LVEF <35% or
<40%, who presented with non-sustained ventricular
tachyarrhythmias and inducible ventricular tachycardia
(21,22). The decrease in overall mortality by ICD was 55%
and nearly 75% for arrhythmic mortality. The more recent
results of MADIT II have confirmed the effectiveness of ICD
in patients who, instead of being selected on the basis of
rhythmic criteria, were enrolled if they had a LVEF <30%
after >1-month-old MI (23). In MADIT II, where the majority
of patients remained in NYHA functional class I or II despite
treatment with angiotensin-converting enzyme (ACE) inhi-
bitors in 75% and beta-adrenergic blockers in 70%, the pro-
phylactic implantation of ICD lowered overall mortality by
31% and arrhythmic mortality by 61% at 2 years. The benefit
conferred by the ICD was even greater among patients
whose QRS complex on surface ECG was >120 ms, with a
lowering of overall mortality reaching 63%. The results of
MADIT II also showed a highly significant lowering of the
rate of sudden cardiac death in the ICD-treated group com-
pared to the control group, and a slightly higher rate of
death from non-sudden cardiac causes in the ICD-treated
group, although the difference was not statistically signifi-
cant (p=0.32). It is also noteworthy that, in survivors of MI,
the benefit conferred by the ICD was distinctly greater in
the subgroup with very severe LV dysfunction (LVEF <25%),
whether in primary or secondary prevention trials (17-19,
21-23). Finally, in the DINAMIT trial, the implantation of an
ICD within 40 days after onset of acute MI had no effect on
long-term, all-cause mortality (24).
In patients suffering from non-ischemic cardiomyopa-
thies, the debate pertaining to the primary prevention of
sudden death has been rekindled by the recently published
results of the SCD-HeFT trial (25). The CAT and AMIOVIRT
trials had previously shown no benefit conferred by ICD on
all-cause mortality in patients suffering from non-ischemic
cardiomyopathies (26,27). The results of the DEFINITE study
showed a slightly lower overall mortality in the ICD-treated
than in the control group, although the difference was not
statistically significant (p=0.08). In contrast, the rate of
sudden death due to ventricular tachyarrhythmias was
significantly lower in the ICD-treated group. Furthermore, a
subgroup analysis showed a significantly lower overall mor-
tality in patients treated with an ICD who were in NYHA
functional class III, though this type of post hoc analysis
needs to be interpreted with caution (28).
The SCD-HeFT trial included over 2500 patients suffering
from ischemic or non-ischemic cardiomyopathies, in NYHA
CHF functional classes II or III, and with a LVEF <35% (25).
The mean age of the population was 60 years, and mean
LVEF was 25%. Ischemic and non-ischemic cardiomyopathies
were evenly distributed. ACE inhibitors or angiotensin
receptor blockers (ARB) were administered to 96%, beta-
adrenergic blockers to 70%, spironolactone to 20%, and loop
diuretics to 80% of patients. The study population was divi-
ded into a placebo-treated group, a group treated with
amiodarone in doses adjusted for body-weight, and an ICD-
treated group. The yearly mortality was 7% (i.e. 35% at
5 years in the placebo-treated group), and survival in the
group of patients treated with amiodarone was the same. In
contrast, in the ICD-treated group, the 5-year overall mor-
tality was 23% lower, corresponding to a 7% lower absolute
risk of death. Analyses of pre-specified subgroups revealed
a greater survival benefit conferred by the ICD to patients
in NYHA functional class II than class III, and a similar bene-
fit in patients suffering from ischemic and non-ischemic
cardiomyopathy.
Finally, the results of the COMPANION trial confirmed the
effectiveness of ICD therapy in patients with ischemic or
non-ischemic cardiomyopathies (6). The 1520 patients
included in this trial were CRT candidates, defined as
severe CHF (NYHA functional class III or IV), a LVEF <35%, a
>120 ms QRS duration, and a >150 ms PR interval. All
patients were treated with an optimal drug regimen and
had been hospitalized for management of CHF within the
prior 12 months. No patient had an indication for implanta-
tion of an ICD. The mean age of the population was
67 years, 87% were in NYHA functional class III, mean LVEF
was 20% and mean QRS duration was 160 ms. Ischemic car-
diomyopathy was the underlying disease in 55% and left
bundle branch block was present in 70% of patients. Treat-
ment with an ACE inhibitor or ARB was administered to 90%,
beta-adrenergic blockers to 70% and spironolactone to 55%
of patients. The study population was divided into three
groups in a 1:2:2 ratio to receive optimal medical regimen
only, optimal medical regimen + CRT, or optimal medical
regimen + CRT + ICD. This trial showed that CRT, with or
without ICD, lowered the primary endpoint of death from
all causes and hospitalizations by 20%, a statistically signifi-
cant treatment effect. Deaths or rehospitalizations for
management of cardiovascular events were decreased by
30% in both groups treated with CRT compared with the
group assigned to optimal medical regimen only, and the
combined endpoint of deaths and hospitalizations for mana-
gement of CHF was decreased by 35% in both groups assi-
gned to CRT. However, the secondary study endpoint of all-
cause mortality was significantly lowered (by 36%) in the
CRT + ICD group only, compared with the group assigned to
the optimal medical regimen. CRT + optimal medical the-
rapy decreased overall mortality by 24% compared with an
optimal medical regimen only, a difference that approa-
ched significance (p=0.06). It should be emphasized, howe-
ver, that the COMPANION trial was not designed to compare
CRT with ICD therapy.
The recently published results of CARE-HF further com-
plicate the debate. At the end of a mean follow-up of
29 months, CRT associated with optimal medical therapy
had lowered the combined endpoint of all-cause mortality
and rehospitalizations for cardiac causes by 37% (p<0.001),
as well as overall mortality by 36% (p<0.002) (7). The
approximate 35% rate of sudden death was similar in both
groups. However, the CARE-HF trial extended to a mean of
37 months confirmed the persistence of an overall survival
benefit conferred by CRT (-40%; p<0.0001), along with a
lower rate of CHF-related deaths (-45%; p=0.003), and a
highly significant reduction in the rate of sudden deaths
(-46%; p=0.005). A study from the Netherlands revealed
that, at the end of a mean follow-up of 18 months, appro-
priate ICD therapy had been delivered to 35% of recipients
of CRT-D systems implanted for secondary, and 21% of reci-
pients of CRT-D systems implanted for primary prevention
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(29). It is noteworthy that, in this study, no predictor of
appropriate ICD therapy was identified. 
While CHF is a syndrome that predominantly affects
populations approaching 75 years of age, these various cli-
nical studies enrolled patients between the ages of 60 and
65 years. Furthermore, patients suffering from CHF often
present with major comorbidity. A clear-cut strategy with
regard to the implantation of CRT-P versus CRT-D devices
cannot be proposed. A crude solution would consist of
implanting a CRT-D system in all CRT candidates. This
seems inappropriate however, because of the widely diffe-
rent costs of devices (CRT-D are 3-5 times more expensive
than CRT-P), and the old age and major comorbidity of
some of the candidates. In some patients, the indication
might be strictly functional, which does not justify the
implantation of a CRT-D (30). The MADIT II trial, for exam-
ple, showed no benefit conferred by ICD in patients whose
glomerular filtration rate was <35 ml/min/1.73 m2 (31).
Therefore, in CRT candidates with a secondary prevention
indication for an ICD, CRT-D should be implanted systema-
tically, provided that, physiologically, they are in an
“acceptable” state of health. In CRT candidates who have a
primary indication for ICD implant, the physiological state
must be scrutinized even more rigorously when choosing a
device. Young patients, who are, by definition, potential
cardiac transplantation candidates, should undergo implan-
tation of a CRT-D, regardless of whether they present with
an ischemic or non-ischemic cardiomyopathy. Conversely,
for elderly patients with major concomitant illnesses and a
limited life-expectancy, the choice of CRT-P appears more
reasonable. The “gray zone” in-between these two types of
populations represents the main challenge. Patient and
relatives must be thoroughly informed of the benefit and
disadvantages offered by each type of device, particularly
of the risk of inappropriate shocks and lead fractures asso-
ciated with CRT-D therapy. 
Importance of independent right 
and left ventricular channels
New developments in the design of atrio-biventricular devi-
ces provide independent left and right ventricular channels.
This important technologic progress has lowered the rate of
re-operation for dysfunctional external connectors that
were used in the early applications of CRT. The advantages
offered by these independent ventricular channels include
the selective sensing of right and left ventricular activity,
and the separate programming of left and right ventricular
stimulation output. The latter might be particularly impor-
tant in cases of high capture thresholds, particularly at the
LV lead, in cases of phrenic nerve stimulation, or when LV
versus RV lead impedance is markedly different. Finally,
new CRT-D devices allow the programming of interventricu-
lar delay and sequential activation of the ventricles. Single-
center studies performed in small numbers of patients have
shown an increase in LVEF and cardiac output, better left
intraventricular resynchronization, and mitigation of mitral
regurgitation by sequential RV and LV, compared with
simultaneous ventricular stimulation (32,33). These
noteworthy observations need to be verified in larger pros-
pective studies. The RHYTHM ICD II study, which compared
an optimized VV delay based on echocardiographic measu-
rement of stroke volume versus simultaneous biventricular
stimulation (VV delay = 0 ms) found no clinical benefit
conferred by an optimized VV delay (34).
Diagnostic and prognostic tools 
for heart failure
Recipients of atrio-biventricular systems are primarily
patients who suffer from CHF. The latest generation of
devices include tools that allow the evaluation of important
variables such as patient activity and respiratory indices,
which improve the quality of follow-up. The recent results
of the MID-HEFT study, based on measurements of intratho-
racic impedance, have opened noteworthy perspectives
(35). In the presence of pulmonary fluid overload, impe-
dance between the RV lead and pulse generator decreased.
Conversely, after treatment and alleviation of pulmonary
fluid overload, intrathoracic impedance increased. This
study, which included 33 patients hospitalized for cardiac
decompensation, showed that intrathoracic impedance fell
by an average of 12% within 2 weeks before hospitalization.
This study also showed an inverse correlation between
increase in intrathoracic impedance on the one hand and
fall in pulmonary capillary pressure and vascular overload
on the other (r = -0.90; p<0.001). An algorithm based on the
magnitude of fall in intrathoracic impedance might allow
the delivery of a warning to the patient and physician of
impending pulmonary vascular fluid overload, thereby
prompting a reduction in number of hospitalizations or, at
least, a shortening of their duration. Other hemodynamic
variables are under examination or in the process of being
validated, including peak endocardial acceleration, left
atrial pressure, RV pressure, or pulmonary arterial pres-
sure. Currently available devices are also capable of analy-
zing variations in sinus rate, the prognostic importance of
which has been highlighted in several studies (36,37).
Conclusions
The number of CRT-D implants is expected to increase,
even when taking into consideration important factors such
as patient age and comorbidity. The CRT-P versus CRT-D
debate is unlikely to be settled by evidence-based medi-
cine, since1600 patients would be needed per study group,
followed for 3 years, to show a 3.8% absolute decrease in
all-cause mortality by CRT-D compared with CRT-P, with
90% power (8). Devices equipped with separate RV and LV
channels allow more precise programming of several para-
meters and, if confirmed by ongoing studies, the program-
ming of an optimized individual interventricular delay. New
devices allow the evaluation of CHF and optimization of its
management. Cardiac resynchronization is usually delive-
red by biventricular stimulation, although experimental and
uncontrolled clinical studies suggest that isolated LV stimu-
lation might be a viable alternative. Finally, in patients
suffering from CHF, in whom the prevalence of atrial
fibrillation is high, the inclusion of an atrial fibrillation pre-
vention algorithm by atrial stimulation might be valuable.
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Finally, the development of home monitoring should be
very helpful in the next future to detect very early the
heart failure decompensation. 
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